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SUPPLEMENTARY MATERIALS
Supplementary Figure 1: Immunohistochemical staining for FUCA-1 of an archival section from a normal atrophic mammary gland 
(A), from a well differentiated breast cancer (B a), from a breast cancer having an intermediate degree of differentiation (B b), from a poorly 
differentiated breast cancer (B c) and from an intraductal breast carcinoma (B d). Magnification 10×. The arrows point to the staining of 
myoepithelial cells.
Supplementary Figure 2: Kaplan-Meier curves of cancer specific survival by positivity or negativity to FUCA-1 immunostaining in 
LN– ER+ patients (A), in LN–, PR+ patients (B), in LN–, ER+ patients with Ki67 staining higher than 14% (C) and in LN–, PR+ patients 
with Ki67 staining higher than 14% (D). 
Supplementary Figure 3: Kaplan-Meier curves of cancer specific survival by positivity or negativity to FUCA-1 
immunohistochemical staining in Luminal B HER2+ patients. In life table are reported at risk patients and in brackets the breast 
cancer specific deaths for the specific time interval.
Supplementary Table 1: Clinical and pathological characteristics of the breast cancer patients who were successfully 
investigate for FUCA-1
Factors Total case-study204 (100%)
LN–
83 (41%)
LN+
121 (59%)
Age, years
≤35
>35
14 (6.9%)
190 (93.1%)
1 (2.6%)
82 (97.4%)
13 (10.7%)
108 (89.3%)
Mean Age , years
(range)
47.2
(26-55)
46.9
(32-55)
47.4
(26-55)
Histology
Ductal
Lobular 
Medullary
Mucinous
Tubular
167 (81.9%)
18 (8.8%)
5 (2.5%)
7 (3.4%)
7 (3.4%)
61 (73.5%)
7 (8.4%)
5 (6.0%)
4 (4.8%)
6 (7.2%)
106 (87.6%)
11 (9.1%)
-
3 (2.5%)
1 (0.8%)
Grade
1
2
3
24 (11.7%)
92 (45.1%)
88 (43.1%)
19 (22.9%)
44 (53%)
20 (24.1%)
5 (4.1%)
48 (39.7%)
68 (56.2%)
Tumor size, cm
≤2
2–5
≥5
116 (57.1%)
77 (37.9%)
10 (4.9%)
60 (72.3%)
22 (2.5%)
1 (1.2%)
56 (46.7%)
55 (45.8%)
9 (7.5%)
Lymph nodes
1–3 lymph nodes
≥4 lymph nodes
Unknown
77 (37.7%)
43 (21%)
1 (0.8%)
-
-
77 (63.6%)
43 (35.5%)
1 (0.8%)
Stage
I
II
III
Unknown
59 (29%)
90 (44%)
54 (26.5%)
1 (0.5%)
59 (71.1%)
23 (27.7%)
1 (1.2%)
-
-
67 (55.4%)
53 (43.8%)
1 (0.8%)
Recurrence
No
Yes
Unknown
88 (43.1%)
105 (51.5%)
11 (5.4%)
48 (57.8%)
32 (38.6%)
3 (3.6%)
40 (33.1%)
73 (60.3%)
8 (6.6%)
ER
Negative
Positive
46 (22.6%)
158 (77.4%)
17 (20.5%)
66 (79.5%)
29 (24. %)
92 (76%)
PR
Negative 
Positive
59 (28.9%)
145 (71.1%)
17 (20.5%)
66 (79.5%)
42 (34.7%)
79 (65.3%)
Her-2
Negative 
Positive
156 (76.2%)
48 (23.5%)
74 (89.2%)
9 (10.8%)
82 (67.8%)
39 (32.2%)
Ki67
<14%
≥14%
95 (46.6%)
109 (53.4%)
54 (65.1%)
29 (34.9%)
41 (33.9%)
80 (66.1%)
Molecular Subtypes
Luminal A
Luminal B
Her2 non Luminal
TN
Unknown
83 (40.7%)
75 (36.8%)
20 (9.8%)
24 (11.8%)
2 (1%)
51 (61.5%)
15 (18.1%)
5 (6%)
11 (13.2%)
1 (1.2%)
32 (26.5%)
60 (49.6%)
15 (12.4%)
13 (10.7%)
1 (0.8%)
Supplementary Table 2: Protective effect of FUCA-1 expression in LN+ luminal B patients using the covariates of 
stage, grade, age at diagnosis and histological type of tumor 
Variable_ Haz. Ratio Standard Err. P > z 95% Conf. Interval
Stage .9356486   .3536163 0.860 .446–1.96
Grade 1.142308   .3761113 0.686 .599–2.18
Age at diagnosis .992387   .0274734 0.783 .940–1.05
Histologic type .9495623   .3470957 0.887 .464–1.94
FUCA-1 cytoplasmatic .2513416   .1302586 0.008 0.091–0.694
General result of regression: p = 0.04.
Supplementary Table 3: Effect of ER, PR, Ki67 on survival with respect to cytoplasmic expression of FUCA-1 in LN+ 
BC patients
Variables p value
Ki67 (cut-off 14%) ER PR HER2
x 0.14
x 0.03
x 0.02
x x 0.001
x x 0.0009
x 0.04
x x 0.09
x x 0.005
x x 0.009
p values refer to log-rank test obtained for cytoplasmic expression of FUCA-1 in LN+ BC patients positive for the marked 
biomarkers. For example, the p value of 0.14 refers to log-rank test calculated for cytoplasmic expression of FUCA-1 in LN+, Ki67+ 
(cut-off 14%)  BC patients, p value of 0.03 refers to log-rank test calculated for cytoplasmic expression of FUCA-1 in LN+, ER+ BC 
patients, p = 0.02 is related to log-rank test calculated for cytoplasmic expression of FUCA-1 in LN+, PR+ BCt cancer patients; p = 0.01 
refers to log-rank test calculated for cytoplasmic expression of FUCA-1 in LN+, Ki67+ (cut-off 14%) and ER+ BC patients. 
Supplementary Table 4: Data from oncomine [1] 
Cancer type Cell line FUCA-1 Log2 median-centered intensity
Breast carcinoma DU-4475 7,871
Breast carcinoma EVSA-T 4,754
Breast carcinoma MDA-MB-453 4,148
Metablastic breast carcinoma HCC1569 4,806
Breast adenocarcinoma CAL-85-1 7,055
Breast adenocarcinoma CAL-51 6,656
Breast adenocarcinoma AU565 6,388
Breast adenocarcinoma EFM-192A 5,845
Breast adenocarcinoma MDA-MB-361 4,528
Breast adenocarcinoma CAL-120 4,281
Ductal breast carcinoma KPL-1 5,722
Ductal breast carcinoma ZR-75-1 5,591
Ductal breast carcinoma JIMT-1 3,187
Ductal breast carcinoma HCC1428 1,361
Invasive ductal breast carcinoma HCC1419 7,472
Invasive ductal breast carcinoma CAL-148 5,949
Invasive ductal breast carcinoma HCC2218 5,340
Invasive ductal breast carcinoma HCC1937 4,997
Invasive ductal breast carcinoma HCC1954 4,885
Invasive ductal breast carcinoma BT-549 4,589
Invasive ductal breast carcinoma HCC11433 3,734
Supplementary Table 5: Sequence of primers and cycling conditions used for q-RT-PCR experiments
Gene Primers sequences Cycling conditions
β-Actin Fw primer:
5′-GTGGATCAGCAAGCAGGAGT-3′
Rev primer:
5′-AGGGTGTAACGCAACTAAGTCA-3′
Probe (M
5′-/FAM/CAC CGC AAA TGC TTC-3′
PCR: 2 steps:
Denaturation 95° C, 10 min
40×: 95° C/15 sec; 60° C/1 min
FUCA-1 Fw primer: 
5′-ATG GAC TGA TTG TTC CCA TCT T-3′
Rev primer: 
5′-CCA TGG TTT GGA GGC ATA GA-3′
Probe: 
5′-FAM/AGC CAT TTC /ZEN/CCA ACA GCA AGA AGC-3′
PCR: 3 steps:
Denaturation 95° C, 2 min
45×: 95° C/15 sec; 56° C/30 sec;  
72° C/30 sec
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